Publications by authors named "Carleen Klumpp-Thomas"

Claim this Profile
A
An Assessment of Kinase Selectivity, Enzyme Inhibition Kinetics and in Vitro Activity for Several Bruton Tyrosine Kinase (BTK) Inhibitors.
Ana Corrionero, Xiaohu Zhang, Patricia Alfonso, Patrick J Morris, Carleen Klumpp-Thomas

ACS Pharmacol Transl Sci· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Elucidating molecularly stratified single agent, and combination, therapeutic strategies targeting MCL1 for lethal prostate cancer.
Juan M Jiménez-Vacas, Daniel Westaby, Ines Figueiredo, Alexis De Haven Brandon, Ana Padilha, Carleen Klumpp-Thomas

Nat Commun· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Targeting of IRAK4 and GSPT1 enhances therapeutic efficacy in AML via c-Myc destabilization.
Eric J Vick, Aishlin Hassan, Kwangmin Choi, Joshua Bennett, Tomoya Muto, Carleen Klumpp-Thomas

Leukemia· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Systematic evaluation of Tox21 compounds that target β-adrenergic receptors and their role in cardiotoxicity.
Xi Luo, Li Zhang, Srilatha Sakamuru, Precious A Adesina, Jinghua Zhao, Carleen Klumpp-Thomas

Toxicol Appl Pharmacol· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Direct Co-Targeting of Bcl-xL and Mcl-1 Exhibits Synergistic Effects in AR-V7-Expressing CRPC Models.
Benjamin C Brim, Andres F Leon, Erica L Beatson, Jessica D Kindrick, Kinjal Bhadresha, Carleen Klumpp-Thomas

Cancer Res Commun· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Kinase Inhibitor GNF-7 Is Synthetically Lethal in Topoisomerase 1-Deficient Ewing Sarcoma.
Carly M Sayers, Morgan B Carter, Haiyan Lei, Arnulfo Mendoza, Steven Shema, Carleen Klumpp-Thomas

Cancers (Basel)· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Expanded Tox21 biological assay panel for the prediction of drug-induced liver injury and cardiotoxicity.
Tuan Xu, Masato Ooka, Jinghua Zhao, Srilatha Sakamuru, Deborah K Ngan, Carleen Klumpp-Thomas

Environ Health Perspect· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Profiling the Tox21 Compound Library for Their Inhibitory Effects on Cytochrome P450 Enzymes.
Srilatha Sakamuru, Jameson Travers, Carleen Klumpp-Thomas, Ruili Huang, Kristine L Witt

Int J Mol Sci· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Large-scale human myeloma cell line small molecule compound screen dataset.
V Keith Hughitt, John K Simmons, Sayeh Gorjifard, Aleksandra Michalowski, Kelli Wilson, Carleen Klumpp-Thomas

Sci Data· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
AI-driven discovery of synergistic drug combinations against pancreatic cancer.
Mohsen Pourmousa, Sankalp Jain, Elena Barnaeva, Wengong Jin, Joshua Hochuli, Carleen Klumpp-Thomas

Nat Commun· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Targeting NAD+ Metabolism Vulnerability in FH-Deficient Hereditary Leiomyomatosis and Renal Cell Carcinoma with the Novel NAMPT Inhibitor OT-82.
Susana S Najera, Christopher J Ricketts, Laura S Schmidt, Julia I Medina, Keita Saito, Carleen Klumpp-Thomas

Mol Cancer Ther· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Multi-Component, Time-Course screening to develop combination cancer therapies based on synergistic toxicity.
Michele Ceribelli, Frances Anne Tosto, Xiaohu Zhang, Christopher J Melani, Mark Roschewski, Carleen Klumpp-Thomas

Proc Natl Acad Sci U S A· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Identification of human pregnane X receptor antagonists utilizing a high-throughput screening platform.
Caitlin Lynch, Ryan Margolis, Jacob Niebler, Jameson Travers, Srilatha Sakamuru, Carleen Klumpp-Thomas

Front Pharmacol· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Identification of Environmental Compounds That May Trigger Early Female Puberty by Activating Human GnRHR and KISS1R.
Shu Yang, Li Zhang, Kamal Khan, Jameson Travers, Ruili Huang, Carleen Klumpp-Thomas

Endocrinology· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Activity of the Ubiquitin-activating Enzyme Inhibitor TAK-243 in Adrenocortical Carcinoma Cell Lines, Patient-derived Organoids, and Murine Xenografts.
Yasuhiro Arakawa, Ukhyun Jo, Suresh Kumar, Nai-Yun Sun, Fathi Elloumi, Carleen Klumpp-Thomas

Cancer Res Commun· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
High-Throughput Screening to Advance In Vitro Toxicology: Accomplishments, Challenges, and Future Directions.
Caitlin Lynch, Srilatha Sakamuru, Masato Ooka, Ruili Huang, Carleen Klumpp-Thomas

Annu Rev Pharmacol Toxicol· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dynamics of SARS-CoV-2 Seroprevalence in a Large US population Over a Period of 12 Months.
Maria Karkanitsa, Yan Li, Shannon Valenti, Jacquelyn Spathies, Sophie Kelly, Carleen Klumpp-Thomas

medRxiv· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Drug combinations identified by high-throughput screening promote cell cycle transition and upregulate Smad pathways in myeloma.
Tyler J Peat, Snehal M Gaikwad, Wendy Dubois, Nana Gyabaah-Kessie, Shuling Zhang, Carleen Klumpp-Thomas

Cancer Lett· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Preclinical Evaluation of the FGFR-Family Inhibitor Futibatinib for Pediatric Rhabdomyosarcoma.
Jerry T Wu, Adam Cheuk, Kristine Isanogle, Christina Robinson, Xiaohu Zhang, Carleen Klumpp-Thomas

Cancers (Basel)· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Development of an assay pipeline for the discovery of novel small molecule inhibitors of human glutathione peroxidases GPX1 and GPX4.
Dorian M Cheff, Qing Cheng, Hui Guo, Jameson Travers, Carleen Klumpp-Thomas

Redox Biol· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
High-throughput approaches to uncover synergistic drug combinations in leukemia.
Emma J Chory, Meng Wang, Michele Ceribelli, Aleksandra M Michalowska, Stefan Golas, Carleen Klumpp-Thomas

SLAS Discov· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CellMinerCDB: NCATS Is a Web-Based Portal Integrating Public Cancer Cell Line Databases for Pharmacogenomic Explorations.
William C Reinhold, Kelli Wilson, Fathi Elloumi, Katie R Bradwell, Michele Ceribelli, Carleen Klumpp-Thomas

Cancer Res· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Preclinical validation of a novel therapeutic strategy for choroid plexus carcinoma.
Brice Martin, Tyler Garman, Madeline Laramee, Amy Wang, Xiaohu Zhang, Carleen Klumpp-Thomas

J Control Release· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
High-throughput and targeted drug screens identify pharmacological candidates against MiT-translocation renal cell carcinoma.
Martin Lang, Laura S Schmidt, Kelli M Wilson, Christopher J Ricketts, Carole Sourbier, Carleen Klumpp-Thomas

J Exp Clin Cancer Res· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
mTOR inhibition overcomes RSK3-mediated resistance to BET inhibitors in small cell lung cancer.
Anju Kumari, Lisa Gesumaria, Yan-Jin Liu, V Keith Hughitt, Xiaohu Zhang, Carleen Klumpp-Thomas

JCI Insight· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis